Abstract
Introduction: Hodgkin’s lymphoma (HL) is largely a curable disease with excellent prognosis. The standard of care in patients with relapsed disease has been to try salvage chemotherapy followed by an autologous stem cell transplantation (ASCT). Managing the patients who relapse after ASCT, is challenging. With the approval of targeted therapies such as PD-1 inhibitors, brentuximab vedotin, the outcomes have improved greatly. Areas covered: This review summarizes the current data available on the newer therapies as well as the present strategies used to treat patients with relapsed HL after an autologous stem cell transplantation. Expert commentary: The approval of brentuximab vedotin and PD-L1 inhibitors has ushered in a new era of targeted therapy in HL. There are currently several targeted therapies under investigation, particularly in the setting of relapsed disease. The current challenges faced are how best to integrate these newer therapies into the existing treatment regimens, finding a right combination with minimal toxicities, role of allogenic transplant in the era of targeted therapy.
Original language | English (US) |
---|---|
Pages (from-to) | 293-300 |
Number of pages | 8 |
Journal | Expert Review of Hematology |
Volume | 11 |
Issue number | 4 |
DOIs | |
State | Published - Apr 3 2018 |
Keywords
- Hodgkins Lymphoma
- Second relapse
- allogenic stem cell transplantation
- brentuximab
- nivolumab
- relapsed Hodgkin lymphoma
ASJC Scopus subject areas
- Hematology